Currently, a novel mTOR inhibitor, LY3023414 is administered in pediatric patients carrying targetable mutations of the TSC (Tuberous sclerosis complex)/PI3K/mTOR pathways (NCT03213678). Here, MTOR is linked to tuberous sclerosis.